$VMD

Frazier William sold $117K of VMD

Frazier William (Chief Medical Officer) sold 10,000 shares of VIEMED HEALTHCARE, INC. (VMD) at $11.72 ($0.12M total) on 2026-06-25.

Original reporting
SEC EDGAR · Frazier William
Published Jun 26, 2026, 4:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 6, 2026, 6:59 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$VMD
Neutral
medium confidence
Mentioned
$VMD
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$VMDNeutralLow
01

Why it matters

The newest fact is the specific open-market sale size, price, and post-transaction holdings by the Chief Medical Officer.

02

Market read

Traders may monitor VMD for follow-on insider activity, but the disclosure alone does not change the company’s fundamentals.

03

What to watch

The filing does not disclose reasons for the sale, whether other insiders sold/bought, or any concurrent operational updates that would connect the transaction to fundamentals.

Relevance 4/10Novelty 4/10Timing: filed 2026-06-26, sale dated 2026-06-25

Background

The article is an SEC Form 4 insider transaction disclosure for VIEMED Healthcare, Inc. (VMD).

Company-level read

Ticker impact

$VMDNeutralMedium confidence
Context

Form 4 shows CMO Frazier William sold 10,000 shares of VIEMED Healthcare at $11.72 on 2026-06-25, totaling $117,200.

Expected impact

Low likelihood of a sustained price move; any reaction is likely limited to short-term sentiment around insider selling.

Evidence & confidence

The filing is a primary-source Form 4, but it provides no new company performance, guidance, or deal information. Insider sales often have non-informational explanations, and the article lacks follow-on context.

Market effects

No sector-level implications; this is company-specific insider transaction disclosure.

None indicated.

None indicated.

Counterpoint

The sale may be routine liquidity or tax-related, and the absence of a stated 10b5-1 plan does not necessarily imply negative information.

Key entities

  • VIEMED HEALTHCARE, INC.

    Subject of the Form 4 insider transaction disclosure.

  • Frazier William

    Chief Medical Officer who sold 10,000 shares.

  • SEC Form 4

    Primary-source insider transaction report filed 2026-06-26.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$VMDMedAI 8/10

Viemed Healthcare Targets Low-20% Growth as Home Ventilation Opportunity Expands

Viemed Healthcare (NASDAQ: VMD) anticipates low-20% revenue growth in 2026, with projected revenue of $317M and EBITDA of $66M. The company's ventilator business averages $1,050 monthly per rental, with an average patient length of 17 months. Viemed has expanded into sleep therapy, maternal health, and other areas, completing three acquisitions in the past three years. The company has no net debt and has repurchased nearly 700,000 shares. Management sees organic growth and strategic acquisitions

Med

Viemed Healthcare Announces New Share Repurchase Program of Up to 5% of Shares Outstanding – Minichart

Viemed Healthcare reported Q2 2026 revenue of $78.1M (up 24% Y-o-Y) and Adjusted EBITDA of $13.7M. The company announced a new share repurchase program for up to 5% of outstanding shares, following a strong first half with 680,802 shares repurchased. Full-year 2026 guidance is $314M-$320M in revenue and $64M-$68M in Adjusted EBITDA. The company has a strong balance sheet with $10.7M in cash and no net debt as of June 30, 2026.

$VMDMedAI 8/10

Viemed (VMD) Q2 2026 Earnings Call Transcript

Viemed Healthcare (VMD) reported Q2 2026 revenue of $78.1M, up 24% year over year, with ventilator patient counts reaching 12,635. Adjusted EBITDA was $13.7M (17.6% margin) and net income was $2.8M. Full-year 2026 revenue guidance was raised to $314M-$320M and adjusted EBITDA to $64M-$68M.

$VMDMedAI 8/10

Viemed Healthcare Q2 Earnings Call Highlights

Viemed Healthcare (NASDAQ:VMD) reported Q2 updates on home respiratory and sleep therapies. Management cited improved ventilator patient growth and said PAP setups rose, with sleep patients up about 5% sequentially and 44% YoY. Equipment sales nearly doubled to $19M. Gross profit was $45M (57.7% margin). Full-year net revenue guidance raised to $314M-$320M and adjusted EBITDA to $64M-$68M.